LEP and obesity disorder: In a high‐fat diet mouse model, treatment with P‐G3‐Chol (5) NPs in diet‐induced obese mice with established obesity resulted in a 15% reduction in body weight, a 45% reduction in fat mass, and a 50% reduction in the eWAT depot size, while improving glucose tolerance.[205] These examples demonstrate that the multifunctional design of nanocarriers can be specifically tuned for different pathological stages of obesity (such as fat browning disorders and central leptin resistance).